September 13, 2018

Windsor’s Scapa to expand wound care footprint with acquisition

Windsor skin care products provider Scapa Healthcare said Thursday it has agreed to acquire an England-based maker of wound care products.

Scapa said acquiring Systagenix, and its 335,000-square-foot manufacturing facility, will "significantly" add to the Windsor company's wound care footprint. Financial terms were not disclosed for the deal expected to be completed in October.

Under the deal, Systagenix's sterilization services and research and development functions will also be transferred to Scapa.

This marks Scapa's second acquisition in 2018.

In March, the Windsor company announced it acquired Dallas-based BioMed Laboratories, a maker of over-the-counter pharmaceutical, medical device, wound care and skin care products.

The $19 million deal includes a cash consideration of up to $13 million. The amount depends on performance in 2018 and 2019.

Free E-Newsletters

Sign up now for our daily and weekly
e-newsletters! Click Here

Today's Poll Does your company use social media to recruit for open positions?<>
Most Popular on Facebook
Copyright 2017 New England Business Media